ES2179064T3 - Procedimiento para la preparacion de lipoproteina reconstituida. - Google Patents

Procedimiento para la preparacion de lipoproteina reconstituida.

Info

Publication number
ES2179064T3
ES2179064T3 ES94810753T ES94810753T ES2179064T3 ES 2179064 T3 ES2179064 T3 ES 2179064T3 ES 94810753 T ES94810753 T ES 94810753T ES 94810753 T ES94810753 T ES 94810753T ES 2179064 T3 ES2179064 T3 ES 2179064T3
Authority
ES
Spain
Prior art keywords
lipid
apoliprotein
detergent
found
rhdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94810753T
Other languages
English (en)
Inventor
Peter Lerch
Gerhard Hodler
Vreni Foertsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring AG
Original Assignee
ZLB Bioplasma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZLB Bioplasma AG filed Critical ZLB Bioplasma AG
Application granted granted Critical
Publication of ES2179064T3 publication Critical patent/ES2179064T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Heating, Cooling, Or Curing Plastics Or The Like In General (AREA)

Abstract

SE ELABORAN PROTEINAS RECONSTITUIDAS DE ALTA DENSIDAD (RHDL) A BASE DE APOLIPROTEINAS Y LIPIDOS, DONDE UNA SOLUCION APOLIPROTEINA ACUOSA CON UNA CONCENTRACION DE 1 - 40 G PROTEINA/L SE MEZCLA CON UNA SOLUCION DETERGENTE-LIPIDO ACUOSA, QUE PUEDE SER LIBRE DE DISOLVENTES ORGANICOS, DONDE LA RELACION MOLAR DEL LIPIDO AL DETERGENTE SE ENCUENTRA DESDE 1 : 0,5 HASTA 1 : 4 Y LA RELACION EN PESO DE LA APOLIPROTEINA CON RESPECTO AL LIPIDO SE ENCUENTRA DESDE 1 : 1,5 HASTA 1: 5, SIENDO ENCUBADAS LAS MEZCLAS DE DETERGENTE-LIPIDO-APOLIPROTEINA OBTENIDAS A CONTINUACION EN UNA TEMPERATURA EN LA ZONA DE LA TRANSFORMACION DE FASE + -10 PARCIALMENTE. LAS RHDL SON APROVECHABLES PARA TRATAMIENTOS PROFILACTICOS Y TERAPEUTICOS DIFERENTES DE ENFERMEDADES, QUE SE ENCUENTRAN EN RELACION CON SUSTANCIAS DE LIPIDOS Y SUSTANCIAS SIMILARES A LIPIDOS. EL PRESENTE PROCESO ES APROPIADO ESPECIALMENTE PARA LA ELABORACION TECNICA E INDUSTRIAL.
ES94810753T 1993-12-31 1994-12-28 Procedimiento para la preparacion de lipoproteina reconstituida. Expired - Lifetime ES2179064T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93810920 1993-12-31

Publications (1)

Publication Number Publication Date
ES2179064T3 true ES2179064T3 (es) 2003-01-16

Family

ID=8215104

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94810753T Expired - Lifetime ES2179064T3 (es) 1993-12-31 1994-12-28 Procedimiento para la preparacion de lipoproteina reconstituida.

Country Status (17)

Country Link
US (1) US5652339A (es)
EP (1) EP0663407B1 (es)
JP (1) JP3553669B2 (es)
KR (1) KR0184027B1 (es)
CN (1) CN1056154C (es)
AT (1) ATE220072T1 (es)
CA (1) CA2138925C (es)
CZ (1) CZ283620B6 (es)
DE (1) DE59410149D1 (es)
DK (1) DK0663407T3 (es)
ES (1) ES2179064T3 (es)
FI (1) FI113052B (es)
HU (1) HU227382B1 (es)
NO (1) NO316762B1 (es)
PL (1) PL185414B1 (es)
PT (1) PT663407E (es)
TW (1) TW434253B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932536A (en) * 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
AUPN030794A0 (en) 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
SE9702776D0 (sv) * 1997-07-22 1997-07-22 Pharmacia & Upjohn Ab Method of preparing pharmaceutical compositions
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
CA2375868C (en) * 1999-06-02 2012-10-30 Vessel Research Laboratory Co., Ltd. Stabilized denatured lipoprotein and method for producing thereof
US6514523B1 (en) 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
US7439052B2 (en) * 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US20090017069A1 (en) * 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
DE10035352A1 (de) * 2000-07-20 2002-01-31 Zlb Bioplasma Ag Bern Verfahren zur Behandlung von instabiler Angina pectoris
US7592008B2 (en) * 2000-11-20 2009-09-22 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Membrane scaffold proteins
CN1474831A (zh) 2000-11-20 2004-02-11 ����ŵ˹������ѧ�йܻ� 膜支架蛋白
CA2451633C (en) * 2001-06-25 2010-11-30 Lipid Sciences, Inc. Systems and methods using a solvent for the removal of lipids from fluids
US6991727B2 (en) * 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US20030127386A1 (en) * 2001-06-25 2003-07-10 Bomberger David C. Hollow fiber contactor systems for removal of lipids from fluids
US20060060520A1 (en) * 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
WO2003000381A1 (en) * 2001-06-25 2003-01-03 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
CA2496831A1 (en) * 2002-08-26 2004-03-04 Lipid Sciences, Inc. Treating alzheimers using delipidated protein particles
WO2004073684A2 (en) 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
EP1599598A4 (en) 2003-03-04 2007-08-08 Yeda Res & Dev PON POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, AND COMPOSITIONS AND METHODS USING THE SAME
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
JP2007527387A (ja) * 2003-07-03 2007-09-27 リピッド サイエンシーズ,インコーポレイテッド 脂質含量の低下したhdlの粒子誘導体を製造するための方法及び装置
US6960803B2 (en) * 2003-10-23 2005-11-01 Silicon Storage Technology, Inc. Landing pad for use as a contact to a conductive spacer
JP4534511B2 (ja) * 2004-02-16 2010-09-01 東ソー株式会社 リポ蛋白を含んだ凍結乾燥試料
WO2006069371A1 (en) * 2004-12-22 2006-06-29 Baylor College Of Medicine A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
US7759315B2 (en) * 2005-03-09 2010-07-20 Csl Behring Ag Treatment of inflammatory conditions of the intestine
WO2007149355A2 (en) * 2006-06-16 2007-12-27 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US7956035B2 (en) * 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
ES2442594T3 (es) 2007-03-01 2014-02-12 Csl Limited Tratamiento de la disfunción endotelial en pacientes diabéticos
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
US8734853B2 (en) 2008-11-17 2014-05-27 University Of North Texas Health Science Center At Fort Worth HDL particles for delivery of nucleic acids
US8975389B2 (en) 2009-03-02 2015-03-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
CN101928739B (zh) * 2009-06-22 2014-02-05 吉林圣元科技有限责任公司 一种重组高密度脂蛋白的制备及其应用
WO2011006994A1 (en) 2009-07-16 2011-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Hdl comprising a therapeutic agent and use in therapy
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
WO2011133876A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
EP3492085A1 (en) * 2010-06-30 2019-06-05 CSL Limited A reconstituted high density lipoprotein formulation and production method therof
WO2012028525A2 (en) * 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Method for producing a lipid particle, the lipid particle itself and its use
WO2012028524A2 (en) * 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Method for producing a lipid particle, the lipid particle itself and its use
US20120190609A1 (en) * 2010-08-30 2012-07-26 Martin Bader Method for producing a lipid particle, the lipid particle itself and its use
CN104010646A (zh) 2011-12-21 2014-08-27 Csl有限公司 用于载脂蛋白制剂的剂量方案
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
ES2608857T3 (es) 2012-12-18 2017-04-17 Salipro Biotech Ag Partículas Salipro
HK1225737B (en) 2013-08-08 2017-09-15 Csl Limited Ways to remove contaminants
LT3043814T (lt) 2013-09-13 2021-02-25 Salipro Biotech AB Antigenas ir jo gamybos būdas
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
TWI576114B (zh) * 2013-12-27 2017-04-01 國立交通大學 一種脂蛋白b重組脂質球,其製備方法及其用途
US20170369872A1 (en) 2014-12-18 2017-12-28 Alnylam Pharmaceuticals, Inc. Reversir tm compounds
CN107708670A (zh) 2015-06-01 2018-02-16 奥托泰利克有限责任公司 磷脂包衣的治疗剂纳米颗粒和有关的方法
JP7550448B2 (ja) 2017-11-22 2024-09-13 エイチディーエル セラピューティクス インコーポレイテッド 血漿処理システムの流体回路をプライミングするシステムおよび方法
AU2018396009A1 (en) 2017-12-28 2020-07-16 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
CN110551207B (zh) * 2019-08-21 2023-05-05 广州蕊特生物科技有限公司 一种脂蛋白纯化方法
WO2021191266A1 (en) 2020-03-25 2021-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hdl for the treatment of lung infections
IL322261A (en) 2023-02-09 2025-09-01 Alnylam Pharmaceuticals Inc Reverser molecules and methods of using them
WO2026008645A1 (en) 2024-07-02 2026-01-08 Institut National de la Santé et de la Recherche Médicale Aerosolization of apolipoprotein a1 nanoparticles enriched with alpha-1-antitrypsin for the treatment of pulmonary emphysema in patients suffering from alpha-1 antitrypsin deficiency

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE456136B (sv) * 1985-06-17 1988-09-12 Oncholab Ab Forfarande for framstellning av en med ett lipofilt biologiskt aktivt emne bemengd berare pa basis av rekonstituerat ldl (lagdensitetslipoprotein)
FR2609399A1 (fr) * 1987-01-13 1988-07-15 Ire Celltarg Sa Procede d'incorporation d'un ou plusieurs principes actifs lipophiles dans des lipoproteines, lipoproteines obtenues et composition pharmaceutique les contenant
US5128318A (en) * 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
DE3854940T2 (de) * 1987-05-20 1996-07-11 Rogosin Inst Rekonstituierte hdl-teilchen und ihre verwendung
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
EP0644897B1 (en) * 1992-06-12 1998-09-16 N.V. Innogenetics S.A. New peptides and proteins, process for their preparation and their use as cholesterol acceptors

Also Published As

Publication number Publication date
DK0663407T3 (da) 2002-10-28
CZ283620B6 (cs) 1998-05-13
PL185414B1 (pl) 2003-05-30
FI113052B (fi) 2004-02-27
NO316762B1 (no) 2004-05-03
KR0184027B1 (ko) 1999-04-01
HUT70448A (en) 1995-10-30
HU9403830D0 (en) 1995-02-28
CA2138925C (en) 2002-11-05
TW434253B (en) 2001-05-16
CZ329994A3 (en) 1995-10-18
JP3553669B2 (ja) 2004-08-11
CN1056154C (zh) 2000-09-06
NO945101D0 (no) 1994-12-30
JPH07242699A (ja) 1995-09-19
EP0663407A1 (de) 1995-07-19
KR950018039A (ko) 1995-07-22
FI946199A0 (fi) 1994-12-30
PT663407E (pt) 2002-11-29
HU227382B1 (en) 2011-05-30
US5652339A (en) 1997-07-29
CA2138925A1 (en) 1995-07-01
ATE220072T1 (de) 2002-07-15
PL306575A1 (en) 1995-07-10
CN1108662A (zh) 1995-09-20
NO945101L (no) 1995-07-03
FI946199L (fi) 1995-07-01
DE59410149D1 (de) 2002-08-08
EP0663407B1 (de) 2002-07-03

Similar Documents

Publication Publication Date Title
Harris et al. Calmodulin and calcium-dependent protease I coordinately regulate the interaction of fodrin with actin.
CA2138925A1 (en) Method of producing reconstituted lipoproteins
DE3883035D1 (de) Saponinkomplexe mit phospholipiden und sie enthaltende pharmazeutische und kosmetische zusammensetzungen.
EP0275005A3 (en) Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them
BR9607999A (pt) Composiçao e processo de preparaçao de uma composiçao de proteína lipossômica
DK0524968T3 (da) Heterovesikulære lipidvesikler
NO178687C (no) Fremgangsmåte for fremstilling av forenlige, lagringsstabile erythropoietinpreparater
FI905956A0 (fi) Foerfarande foer producering av ett biologiskt aktivt protein.
ATE131471T1 (de) An fette gebundene aminosäuren, peptide oder deren derivate
DE69130113D1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
DK0478686T3 (da) Flour- og phosphorholdige amphiphile molekyler med overfladeaktive egenskaber
RU94042240A (ru) Антагонисты рецепторов возбужденных аминокислот, способ получения, промежуточные соединения, фармацевтическая композиция
BR0316402A (pt) vesìcula fusogênica, métodos para preparar uma vesìcula fusogênica encapsulante, e para encapsular pelo menos uma substáncia terapêutica ou imunologicamente ativa em uma vesìcula fusogênica, uso de uma vesìcula fusogênica, e, formulação farmacêutica
OA06421A (fr) Procédé de préparation de dérivés N-(vinblastinoyl-23) d'acides aminés et de peptides.
ES8801118A1 (es) Un metodo para preparar liposomas a base de un fosfolipeno un agente hidratante y un farmaco encapsulado.
MX9207334A (es) Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
ATE321859T1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
PT95114A (pt) Processo para a preparacao de misturas de proteinas, peptidos e aminoacidos com a composicao optimizada para servirem como alimento de recem-nascidos e crias de mamiferos e como complemento de leite humano
ATE136211T1 (de) Zielliposomen und verfahren zur kupplung von liposomen-proteinen
AU3499889A (en) Cosmetic products containing milk constituents
BR0116122A (pt) Peptìdeos e/ou proteìnas bem como seu uso para preparar uma composição farmacêutica, terapêutica e/ou preventiva
ES2106096T3 (es) Procedimiento para asegurar glutation intracelular adecuado en el tejido.
Cochrane et al. Protein-phospholipid interactions in pulmonary surfactant: the Parker B. Francis lectureship
PT71408A (de) Verfahren zur herstellung von 1-alkadien-2,4-yl-2-hidroxymethyl-3,4,5-trimydroxypiperidinen mit wirkung uber die kohlehydraten und/oder fettwechsel und von diesen verbindungen enthaltenden pharmazeutischen und/oder tierartzleichen praparaten
ATE210184T1 (de) Ungespleisste varianten des gp350/220